Boston Scientific Outlines Growth Trajectory at Strategic Decisions Conference
Boston Scientific Corporation (BSX) provided insights into its business strategy and market positioning during the Bernstein 42nd Annual Strategic Decisions Conference on May 27, 2026. Chairman, President, and CEO Michael Mahoney and Senior Vice President & Global Chief Medical Officer Ken Stein represented the company at the event.
Company Performance and Market Opportunities
Michael Mahoney acknowledged the company’s significant growth, noting that Boston Scientific has evolved from a period of modest expansion to achieving 16% organic growth in recent years. He highlighted the company’s strategic focus on markets that are projected to grow at a minimum of 8%, as previously communicated at last year’s Investor Day.
Mahoney expressed pride in the company’s development and its competitive presence in attractive growth sectors. He pointed to recent strategic moves, including investments in companies like MiRus and developments related to the Penumbra shareholder vote, as examples of the company’s proactive approach to investing and expanding its capabilities.
The CEO indicated that 2026 is viewed as a transitional year, suggesting ongoing strategic adjustments and investments to sustain and accelerate future growth. Further details on the company’s performance and outlook are expected to be shared as the conference progresses.
